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Tumor evolution presents a formidable obstacle that currently prevents the development
of truly curative treatments for cancer. In this perspective, we advocate for the hypothesis
that tumor cells with significantly elevated genomic content (polyploid tumor cells) facilitate
rapid tumor evolution and the acquisition of therapy resistance in multiple incurable cancers.
We appeal to studies conducted in yeast, cancer models, and cancer patients, which all con-
verge on the hypothesis that polyploidy enables large phenotypic leaps, providing access to
many different therapy-resistant phenotypes. We develop a flow-cytometry based method
for quantifying the prevalence of polyploid tumor cells, and show the frequency of these
cells in patient tumors may be higher than is generally appreciated.We then present recent
studies identifying promising new therapeutic strategies that could be used to specifically
target polyploid tumor cells in cancer patients.We argue that these therapeutic approaches
should be incorporated into new treatment strategies aimed at blocking tumor evolution
by killing the highly evolvable, therapy-resistant polyploid cell subpopulations, thus helping
to maintain patient tumors in a drug sensitive state.
Keywords: polyploidy, hyperdiploidy, tumor evolution, therapy resistance, tumor initiation, cancer stem cell,
aneuploidy, chromosomal instability
COMING TO TERMSWITH CANCER AS A RAPIDLY EVOLVING
SYSTEM
It has long been appreciated that cancer is an evolutionary system
(1). In this paradigm, individual cancer cells are the reproduc-
tive units within a tumor, with those cells that acquire a survival
advantage through random genetic change being selected through
multiple rounds of clonal expansion, during which they acquire
further alterations that eventually combine to produce malignant
phenotypes (1). The ability of a tumor to evolve solutions to selec-
tion pressures is a function of the selectable heritable variation that
is present within the tumor, be it internal stressors such as low
oxygen tumor micro-environments, or external stressors such as
anti-cancer therapies (2–8). The paradigm of selectable heritable
variation at the cellular level being a critical driver of cancer biol-
ogy has been captured by the term tumor heterogeneity, and the
emerging consensus is that tumor heterogeneity remains a fun-
damental obstacle preventing the development of truly curative
anti-cancer therapies (2–8).
The introduction of efficacious targeted therapies highlighted
the central role of evolution in cancer therapy failure. Patients with
leukemia and lung cancer treated with specific inhibitors target-
ing oncogenic receptor tyrosine kinase (RTK) activity, eventually
exhibit disease progression driven by point mutations within the
oncogenic RTK that renders the tumor resistant to further ther-
apy (9–11). Retrospective analysis revealed rare therapy-resistant
mutants present in tumors prior to treatment initiation (12),
confirming that in some cases targeted therapy selected for resis-
tant clones that were already present within the tumor system.
Melanoma offers a compelling case study of tumor evolution
during targeted therapy. The identification of oncogenic muta-
tions within the B-Raf kinase led to the development of specific
inhibitors that initially display phenomenal clinical efficacy (13–
16), which is swiftly followed by disease recurrence driven by
rapidly evolving therapy resistance [reviewed in Ref. (17)].
Immunological based therapies are also vulnerable to therapy-
resistance driven by tumor evolution, as revealed during a vaccine
strategy trialed in adult patients with Glioblastoma. The vac-
cine therapy invokes a patient immune response that specifically
targets the truncated, oncogenic EGFRvIII variant of the EGF
receptor (18). The EGFRvIII variant is present in approximately
one-third of Glioblastoma patients (19) and is an ideal target
for anti-tumor immunotherapy because the constitutive activ-
ity of the EGFRvIII contributes to tumorigenicity, invasion and
therapy resistance [reviewed in Ref. (18)]. Although the vaccine
significantly increased overall survival time in treated patients
whose tumors expressed the EGFRvIII receptor, disease recur-
rence occurred in all patients with most recurrent tumors losing
EGFRvIII expression (18). EGFRvIII expression is typically het-
erogeneous in Glioblastoma tumors, and is only observed in a
sub-population of tumor cells and rarely in the entire tumor
(20, 21). The most plausible hypothesis is that the vaccine led to
the immune-clearance of EGFRvIII expressing cells from patient
tumors, but in the majority of cases it was the presence of
viable EGFRvIII negative cells within the tumor that allowed
immunological escape and rapid disease recurrence.
These and many other studies all converge on the hypothesis
that long-term cancer patient survival requires the development of
therapeutic strategies that actively suppress tumor evolution (2–8,
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Box 1 Definitions.
Polyploidy: An alteration of chromosomal number that is a multiple of the normal diploid (2n) complement.
Tetraploidy: A specific form of polyploidy that is a doubling of the normal diploid complement (i.e., 4n).
Aneuploidy: An alteration of chromosome number that is not a multiple of the diploid (2n) complement.
Hyperdiploidy: Having a chromosome number that is more than the diploid (2n) complement.
Around 90% of all solid tumors are aneuploid, and most aneuploidy tumors exhibit chromosomal gains and are therefore hyperdiploid (85).
Many cancers have complex karyotypes [see for example Ref. (62)]. In this perspective, we have focused on subpopulations of cancer cells
that have elevated genomic content relative to the tumor bulk, as a source of cells capable of rapid evolution. In the strict sense, these
cells are grossly hyperdiploid relative to healthy, untransformed cells. However, we refer to them here simply as polyploid tumor cells (or
pseudo-polyploid tumor cells) for the following reasons. (1) We are comparing these cells to the tumor bulk, and grossly hyperdiploid tumor
sub-population of cells are typically polyploid (or close to polyploid) relative to the dominant aneuploid tumor karyotype, (2) many of the
cited cell biology studies refer to this tumor cell sub-population as polyploid. We ask the reader to keep in mind that the “tumor polyploid
cells” are in reality a genetically heterogeneous sub-population, which is composed of a variety of complex cancer karyotypes that are
approximately polyploid relative to the dominant, aneuploid tumor cell population.
22). In this perspective, we propose that tumor cells containing an
elevated genomic content (as described in Box 1) are key players in
tumor evolution, and are therefore important therapeutic targets
in preventing the acquisition of therapy resistance during treat-
ment. We begin by summarizing seminal work conducted in yeast
that characterizes how chromosomal gains facilitate rapid evolu-
tion under a wide variety of selection pressures. Next, we review
recent work conducted in cancer, which show that chromosomal
gains also underpin tumor initiation and the acquisition of therapy
resistance in cancer patients. We then present an updated model
of tumor evolution that highlights the central role of increasing
ploidy in cancer initiation and disease progression.
We finish the perspective showcasing recent studies that identify
anti-polyploid compounds that we hope will provide a foundation
for the development of efficacious chemopreventative and evolu-
tionary suppressing cancer therapies of the future. Our goal is
to focus research efforts on the development and translation of
such novel anti-polyploid therapies to prevent and treat incurable
cancers.
HYPERDIPLOIDY AND POLYPLOIDY FACILITATES RAPID
EVOLUTION: LESSONS FROM YEAST THAT ARE RELEVANT
TO CANCER
HOW INCREASING GENOME SIZE FACILITATES RAPID EVOLUTION IN
YEAST
Serious systemic fungal infections continue to endanger patients
with immunocompromised immune systems (23, 24). Anti-fungal
azole drugs are the most commonly used therapy against superfi-
cial and systemic fungal infections due to their efficacy and safety
(23). Fluconazole is a widely used azole that is orally and intra-
venously available and effective against Candida infections, and is
used clinically to treat oropharyngeal and esophageal Candidas
in HIV patients, invasive candidiasis, as well as fungal infec-
tions in the urinary tract and central nervous system (23). Prior
to the HIV pandemic, fluconazole resistance was rare. However,
the widespread use of fluconazole to treat HIV/AIDS patients
has increased the incidence of fluconazole-resistant Candida iso-
lates (25). Generally, resistance develops after administration of
sub-optimal doses of fluconazole over long periods of time, but
in 1992, Bossche et al. isolated a resistant Candida strain in a
patient after only 9 days of fluconazole treatment (26), revealing
circumstances under which the evolution of fluconazole therapy-
resistance occurs astonishingly quickly. In a follow-up study exam-
ining the mechanisms underlying the rapidly acquired fluconazole
resistance, it was found that the resistant strain expressed more
cytochrome P-450 14α-lanosterol demethylase (the target for azole
antifungals) due to duplication of the entire chromosome contain-
ing the CYPO51 gene (27). Subsequent studies have confirmed
that chromosome duplication is an effective and widely utilized
mechanism to evolve drug-resistance in fungal infections (28–31).
Increasing chromosome numbers also provides fitness advan-
tages in other contexts. A powerful example of rapid adaptation
through increasing genomic content was provided by Rancati et al.
(32) when they experimentally perturbed cytokinesis by deleting
the MYO1 gene in the yeast Saccharomyces cerevisiae, and then
selected for mutant strains that had evolved a solution to MYO1
deletion to restore functional cytokinesis. Strikingly, they found
that most of the evolved strains, including the 10 fittest isolates,
displayed an increase in DNA content. Further, diploid strains
evolved much faster than haploid strains. Together, these data
suggest that polyploidization facilitated the rapid evolution of
cytokinesis rescue, a finding reminiscent of the rapid evolution
of therapy-resistance driven by polyploidy described in immuno-
compromised patients treated with anti-fungal therapies described
above.
Hyperosmotic stress occurs when an organism is exposed to
higher solute concentration outside the cell, leading to water
loss and subsequent increases in intracellular ion and metabo-
lite concentrations [reviewed in Ref. (33)]. Hyperosmotic stress
is a common environmental stressor, and yeast have evolved a
hyperosmotic stress response that is mediated by the high osmo-
larity glycerol (HOG) pathway, which activates genes involved in
salt tolerance and adaptation (34). Wagner and colleagues investi-
gated how yeast could evolve adaptations to hyperosmolarity stress
in long-term evolution experiments, where three replicate Sac-
charomyces cerevisiae yeast populations were exposed to high-salt
conditions for 300 generations (33). All three populations evolved
a faster growth rate under high-salt conditions after selection
compared to their ancestral cultures (33). DNA content analy-
sis revealed that all three evolved lines had an increase in ploidy,
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suggesting that evolutionary adaptation to hyperosmotic stress is
also facilitated through increasing genome size (33).
The Evolution Canyon originated in Israel 3–5 million years
ago, and contains diverse micro-environments and has experi-
enced minimal human disturbance, providing an excellent natural
site to study evolutionary adaptations of many organisms (35).
Chang et al. isolated and phenotypically characterized 14 diploid
yeast strains collected from different micro-environments present
within the Evolutionary Canyon (35). One of these strains was
highly resistant to the metal copper. Strikingly, Chang et al. found
that the copper-tolerant phenotype was the product of large-scale
chromosomal rearrangements that increased the copy number of
the CUP1 and CUP2, major genes involved in copper regulation
(35). Additional copper-tolerance gene expression was up regu-
lated by increased CUP2 copy number, showing that the increase
in gene dosage both directly and indirectly contributes to the evo-
lution of copper-tolerance. Surprisingly, when the tolerant strains
were cultured in the absence of copper, a wild-type chromosome
reappeared and was fixed within 300 generations. These findings
reveal that “large-scale chromosomal rearrangements provide not
only fast arising but also readily reversible sources of variation
during early stages of adaptive evolution” (35).
Collectively, these studies reveal increasing chromosome con-
tent as a mechanism that facilitates the rapid evolution of yeast
across many different selection pressures and environments.
These include the rapid acquisition of therapy resistance in
patients, rapid adaptation during experimental evolution, and the
successful adaptation to selection pressures present in nature.
HOW INCREASING GENOME SIZE CHANGES YEAST PHENOTYPES
One important mechanism for rapid adaptation provided by chro-
mosomal gain is increased gene expression due to elevated gene
dosage. Multiple studies have confirmed that messenger RNA lev-
els scale with chromosome copy number in aneuploid systems.
Hughes et al. conducted expression profiling of yeast strains with
characterized aneuploidy and showed that increased genomic con-
tent data “precisely mirrored the expression data in this region”
(36), revealing that gene duplication leads to a commensurate
increase in messenger expression (36). The second important
finding from this study was that under experimental selection,
large-scale gene duplications were shown to be the dominant
adaptive response to loss-of-function deletions (36), providing
early support for the hypothesis that increasing genomic content
facilitates rapid adaptation.
In a later study, examining the effects of extra chromosomes on
cell physiology and cell division in yeast, Torres et al. observed an
approximate doubling of gene expression in duplicated chromo-
somes, with greater than 90% the amplified genes being expressed
at a higher level (37). These data indicate that most genes are
expressed in proportion to their gene copy number, and gene
amplification results in a roughly proportional increase in gene
expression (37).
The classic evolution study by Rancati et al. confirmed that on
average there is a stoichiometric relationship between gene copy
number and gene expression level, with gene expression levels
from chromosomes roughly scaling with chromosome copy num-
ber (32). However, they noted that some gene expression levels
deviated significantly from this trend, identifying outlier genes
whose expression changed more than three standard deviations
away from the stoichiometric trend (32). Further evidence suggests
that the majority of outlier expression is caused by the increased
expression of transcription factors (or their upstream regulators)
caused by chromosomal copy number increase (32). Similarly,
expression of the copper resistance gene CUP2 due to increase
in gene dosage causes the expression of downstream genes, several
of which also enhance resistance to copper (35). This reveals how a
simple linear change in gene expression can generate a non-linear
adaptive response through pathway amplification (35).
Changes in yeast chromosome numbers also increase protein
expression levels in yeast cells. Pavelka et al. generated a panel of
stable aneuploidy yeast strains to directly address this question
(38). They found that chromosomal copy number changes in gen-
eral caused proportional changes in gene expression and protein
expression levels (38). Further, they found that yeast strains with
similar karyotypes tend to display similar changes in global protein
expression patterns (38). Interestingly, the Authors also identified
outliers in gene and protein expression, however only a small frac-
tion of the gene expression outliers overlapped with the protein
expression outliers (38), revealing that gene dosage changes are
likely to have complex effects on cellular phenotypes. The Authors
applied a variety of selection pressures on euploid parent controls
and aneuploid strains, revealing that aneuploid strains grew better
under selection by generating rapid phenotypic variation, show-
ing that aneuploidy that can provide fitness gains under diverse
selection pressures (38).
Together, the data sets summarized above show that increasing
DNA content modifies both gene and protein expression, in linear
and non-linear ways, allowing cell populations to rapidly explore
a wide range of heritable phenotypes. Thus, increasing ploidy
enables yeast cells to experience large phenotypic leaps, which in
turn facilitates rapid evolution to novel selection pressures (39).
HOW INCREASED GENOMIC CONTENT BUFFERS CELLS AGAINST
DELETERIOUS MUTATIONS
The mutator hypothesis proposes that mutations that increase
genomic instability (the mutator phenotype) drives tumorigen-
esis by allowing cells to rapidly acquire the necessary number of
mutations required for cellular transformation (40). The mutator
phenotype was first proposed by Loeb to explain how tumors can
accumulate the number of mutations necessary for tumorigenesis
despite the extremely high accuracy with which mammalian cells
replicate the genome (41, 42). One primary criticism of the muta-
tor hypothesis is that most mutations are deleterious and therefore
the mutator phenotype will accelerate the accumulation of muta-
tions that reduce fitness, leading to negative clonal selection [(3)
and references therein]. Although experimental and theoretical
counters to this criticism have been provided [recently reviewed
in Ref. (43)], one potentially important phenomenon that has
been overlooked in this debate is the role of genome amplifica-
tion in buffering eukaryotic cells against the effects of deleterious
mutations.
Using adaptation to different laboratory environments as their
selection pressure, Thompson et al. (44) compared the relative
fitness of mismatch repair defective (mutator) strains of yeast
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within haploid and diploid yeast genetic backgrounds, with strik-
ing results. In the diploid genetic background, mutators displayed
an advantage over non-mutators, and mutators that “win” adapta-
tion experiments were on average fitter than non-mutator winners
(44). In contrast mutators in the haploid background displayed
no advantage when competed against haploid non-mutators and
the haploid mutator winners were less fit than the haploid non-
mutator controls (44). The most parsimonious explanation for
this result is that most deleterious mutations are recessive, and
are therefore buffered in the diploid yeast strain. Haploid yeast
must bear the cost of deleterious mutations in full, which gives
haploid yeast less time to accumulate beneficial mutations before
the cumulative effects of deleterious mutations eliminates them
from the population. An additional important observation from
this study was the type of mutations that occurred with haploid
versus diploid populations. The diploid mutators displayed a gen-
eralist class of beneficial mutation that provided a large selective
advantage across a range of selection pressures (44). In contrast,
haploid mutators displayed beneficial mutations whose advantage
was limited to the specific stress they were selected under (44).
These results suggest two intriguing hypotheses. First, increases
in ploidy may act co-operatively with a mutator phenotype by
reducing the effect of deleterious mutations. Second, increased
ploidy enables a mutator phenotype to generate “generalist” bene-
ficial mutations that confer selective advantage across a wide range
of stressors.
HOW ELEVATED PLOIDY DRIVES THE EVOLUTION OF CANCER
ANEUPLOIDY AND TUMORIGENESIS
The vast majority of cancers are aneuploidy, with around 90%
of solid tumors and 75% of hematopoietic cancers having abnor-
mal chromosome numbers (45). The high incidence of aneuploidy
in cancer cells inspired Boveri over 100 years ago to propose the
hypothesis that aneuploidy causes cancer (46). Consistent with this
hypothesis, aneuploidy has been shown to precede transformation
in a variety of cancers (47–54), and several studies provide both
experimental and theoretical support for a fundamental role of
aneuploidy during tumor initiation (55–59). Duesberg and col-
leagues have proposed that aneuploidy generates cancer causing
karyotypes that are selected during the evolutionary process of
tumor initiation and transformation (60–62). However, these ideas
have been contested, in part because the aneuploidy model of
tumor initiation is thought to downplay the established role of
oncogenes in the process of transformation (63–65). Recent stud-
ies examining the role of polyploidy in tumor initiation may
help incorporate the oncogenes and aneuploidy tumor initiation
models into a single paradigm.
EVIDENCE SUPPORTING TETRAPLOID CELLS BEING THE CELL OF
ORIGIN IN TUMOR INITIATION
Experimental evidence directly linking tetraploidy with tumor ini-
tiation was provided when Fujiwara et al. created a tetraploid
cell population in p53-null mouse mammary epithelial cells (66).
Tetraploid cells displayed a high level of tumorigenesis when
injected into nude mice, in contrast to the diploid p53-null con-
trols, which did not form tumors (66). Subsequent studies per-
turbing the mitotic spindle led to accumulation of tetraploid cells
and a higher incidence of tumor formation, further supporting a
central role of tetraploidy in tumor initiation (67, 68).
Tetraploidy potentially provides multiple beneficial functions
during tumor initiation. First, a large body of evidence supports
the hypothesis that tetraploidy acts as a gateway karyotype by
inducing chromosomal instability (CIN), which leads to aneu-
ploidy and the evolution of a transformed phenotype [reviewed
in Ref. (69)]. Using several experimental models of telomere crisis,
Davoli and de Lange recently demonstrated that endoreplication
and mitotic failure created tetraploid cells during telomere crisis
(70). Importantly, the resulting tetraploid cells displayed enhanced
tumorigenic capacity relative to diploid controls in soft agar and
mouse implantation assays (70). Finally, Davoli and de Lange
then showed tumors that are initiated by tetraploid cells evolve
more complex aneuploidy karyotypes in vivo, showing tetraploidy
functions as a gateway mutation to aneuploidy (70).
Lv and colleagues used the spontaneous transformation of pri-
mary ovarian epithelial cells to provide compelling evidence for
the role of tetraploidy as a gateway karyotype during tumori-
genesis (71). Lv et al. generated primary cultures of mouse
ovarian surface epithelial cells (MOSECs), which they contin-
ually subcultured for over 30 passages (71). Following ploidy
status during culture revealed that the diploid cells underwent
an intermediate tetraploid phase, and then evolved into aneuploid
(near-tetraploid) cells (71). Tetraploidy was caused by cytokine-
sis failure in diploid cells, with the tetraploid cells subsequently
experiencing chromosome mis-segregation during bipolar and
multipolar mitosis to generate aneuploid progeny (71). When the
lines were re-injected into mice, only late passage aneuploid cells
formed tumors (71), showing that spontaneous transformation
during long-term passaging likely involves a diploid–tetraploid–
aneuploid transition caused by defects in mitosis.
Two recent studies have provided compelling support for the
hypothesis that genome doubling facilitates the acquisition of a
transformed phenotype in tumor initiation in human cancers.
Examining neuroblastomas, Lundberg et al. combined karyotypic
analyses of tumors with mathematical modeling and concluded
that the loss of chromosomes from a tetraploid precursor cell was
the most parsimonious hypothesis explaining the chromosomal
numerical alterations present in neuroblastoma tumors (72). This
conclusion was supported experimentally when it was shown that
neuroblastoma lines displayed a high frequency of polyploidiza-
tion events, and that clonal cultures with elevated genomic content
generated aneuploid progeny with high frequency (72). Altogether
these data suggest that polyploidy is a gateway cell state that
facilitates the generation of aneuploidy and increases karyotypic
complexity in neuroblastoma tumors (72).
More recently, Swanton and colleagues (73) systematically
addressed the role of tetraploidy in colorectal cancer evolution
(73). Colorectal cancers that had undergone genome doubling
(i.e., tetraploid) displayed a significantly higher incidence of
genomic instability than those cancers that began as diploids, with
tetraploidization appearing to be an early event in the majority
of colorectal cancers (73). Tetraploid clones were isolated from
colorectal cancer lines, and these displayed a higher incidence of
segregation errors during anaphase and increased chromosomal
structural abnormalities relative to their cognate, diploid controls
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(73). Strikingly, daughter cells derived from diploid clones that
had undergone a segregation error during mitosis frequently died
or underwent cell-cycle arrest, whereas daughter generated from
tetraploid clones after segregation error died much less frequently
and continued to proliferate (73). These data provide direct exper-
imental support for the hypothesis that tetraploidy endows tumor
precursor cells with an elevated tolerance to CIN, facilitating
the generation of aneuploidy and the evolution of a complex
karyotype (74). Consistent with this model, genome doubling is
associated with poor prognosis, being significantly associated with
disease relapse (73).
In addition to increasing tolerance to aneuploidy and facili-
tating the evolution of a transformed karyotype, tetraploidy also
helps overcome oncogene induced senescence. Aberrant activa-
tion of oncogenes such as Ras, Raf, or PI3-kinase triggers cellular
senescence, which functions as a tumor suppressor by permanently
restricting the proliferative capacity of cells (75–77). Activation
of DNA-damage response pathways plays an important role dur-
ing oncogene induced senescence (78–80), as does activation of
p53 pathways (76, 81–83). Exploring how malignant cells over-
come the senescent barrier, Zheng et al. used a mouse model of
tumorigenesis discovered that cells that overcame tumorigenesis
barriers to drive long-term proliferation in culture all displayed
near-polyploid levels of aneuploidy (84). These near-polyploid
cells overexpressed DNA repair genes to reduce the DNA-damage
response, as well as methylating p53 promoter regions to silence
p53 expression (84). These results indicate that polyploid cells
may be able to overcome the oncogene induced senescence by
increasing DNA repair activity and epigenetic reprograming of
p53 expression (84).
Altogether, these studies show that tetraploidy functions as
a gateway phenotype that cooperates with oncogenes to induce
cellular transformation in three ways. First, tetraploidy helps over-
come oncogene induced senescence. Second, tetraploidy facilitates
the acquisition of oncogenic karyotypes and phenotypes by induc-
ing CIN leading to aneuploidy. Third tetraploidy buffers pre-
malignant cells against the deleterious effects of chromosomal
loss. Collectively, these findings go some way to explaining why the
majority of human tumors contain a hyperdiploid karyotype (85).
POLYPLOIDY TUMOR CELLS AND THE EVOLUTION OF
CANCER THERAPY RESISTANCE
HOW POLYPLOIDY OVERCOMES THERAPY-INDUCED SENESCENCE
Cancer cells can survive chemotherapy and radiotherapy by enter-
ing a reversible senescent state, called therapy-induced senescence
(TIS), which is a senescent-like phenotype that displays many of
the features of the normal physiological senescence phenotype
(86). Even transformed cells lacking functional p53 and retinoblas-
toma protein (Rb) pathways retain the capacity to undergo TIS
(87). TIS has been observed in vivo using both xenograft and
transgenic cancer models (88, 89). Senescence markers have been
observed from breast and lung cancer patient tumor specimens
treated with chemotherapy, supporting the hypothesis that TIS is
a clinically relevant cell fate in human cancer patients treated with
cytotoxic therapies (90, 91).
Unfortunately TIS is not permanent, with rare cells being able
to bypass TIS to re-enter the cell cycle and re-initiate tumor growth
(90). One way cells overcome TIS is through the over-expression
of the mitotic kinase CDK1, which phosphorylates the protein
survivin to promote TIS escape and subsequent survival of can-
cer cells (92). In a follow-up study, Wang and colleagues went
on to show that over-expression of CDK1 induced the forma-
tion of polyploid cells during TIS, and that these CDK expressing
polyploid cells represent an important transition state through
which escape from TIS preferentially occurs (92). Intriguingly,
Wang et al. also reported that non-small cell lung cancer patients
expressing markers of TIS following neo-adjuvant therapy had a
significantly worse prognosis than patients who did not express
TIS markers (92). Altogether, these data support a model whereby
TIS provides an escape mechanism for tumor cells to avoid the
toxic effects of chemotherapy to drive disease recurrence (92).
Moreover, polyploid tumor cells are far more likely to overcome
the TIS barrier, and polyploidy-mediated TIS escape represents an
important new therapy-resistance mechanism in cancer patients
undergoing a variety of chemotherapy regimes (92).
HOW POLYPLOIDY INDUCES INFREQUENT CELL CYCLE
Infrequent cell cycle is a well-established resistance mechanism
against cytotoxic insult. Normal quiescent (G0) hematopoietic
stem cells (HSCs) are resistant to the anti-proliferative chemother-
apeutic agent 5-fluoro-uracil (5-FU) (93, 94), and become sensi-
tive to 5-FU treatment when they are forced into a proliferative
state by treatment with IFNα (95). Healthy HSCs can be pro-
tected from the effects of irradiation by increasing the proportion
of HSCs in G0 through a variety of treatments in vivo (96–
98). In cancer, the chemoprotective effect of cell-cycle-mediated
drug-resistance is well-established (99). For example, Schmidt and
colleagues demonstrated that colon adenocarcinoma cells arrested
in G1 by over-expression of p27Kip1 are significantly more resistant
to a variety of chemotherapeutic agents, including temozolomide
(100). Using a mouse xenograft model, Naumov et al. showed
that the DNA intercalating compound doxorubicin (DXR) effec-
tively reduced the metastatic tumor burden but spared non-cycling
tumor cells, which persisted during therapy and subsequently
developed into metastases after DXR therapy was discontinued
(101). More recently, label-retention has been used to pheno-
typically identify infrequently dividing cells that are resistant to
chemotherapy from a variety of tumor types (102–105). Stud-
ies examining the cancer stem-cell phenotype have also shown
that quiescence provides protection against cell death induced
by DNA-damage agents (106, 107) and chemotherapy (108).
Recently, a landmark study by Kreso et al. revealed how chemother-
apy selects for minor, infrequently cycling subpopulations using
lineage tracking in mouse models of cancer evolution (109). Col-
lectively these studies provide strong support the hypothesis that
infrequent cell cycle as a fundamental mechanism that contributes
to the evolution of therapy resistance in cancer patients.
Recently, we identified a genetically diverse, polyploid tumor
cell sub-population in Glioblastoma patients that is able to ini-
tiate and maintain tumor growth in vivo, and is resistant to
cytotoxic therapy (110). Proliferation markers revealed that the
polyploid tumor cell sub-population contain approximately three
times more quiescent cells than the bulk near-diploid tumor
population (110). Infrequently cycling cells retain the dye CFSE,
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and CFSE label-retention has been used to enrich for therapy-
resistant, tumor-initiating cells in several tumor types [reviewed
in Ref. (111)]. Polyploid tumor cells accumulate within the label-
retaining sub-population of cells, providing a functional confir-
mation of their infrequent cell cycle (110). Altogether, these data
show that increasing chromosome numbers provides a mechanism
to generate infrequently cycling tumor cells, providing a general
resistance mechanism against cytotoxic chemotherapy treatments
designed to target actively cycling cells (110).
Why do polyploid tumor cells cycle less frequently? Seminal
studies conducted in yeast show that increased transcription and
translation caused by elevated genomic content causes cell-cycle
delays during G1 (37). Murine embryonic fibroblasts (MEFs) con-
taining extra chromosome copies also cycle less frequently (112,
113), likely due to changes in transcription and translation (85).
In addition, polyploid tumor cells have a twofold larger cell vol-
ume compared to their diploid counterparts (110). Cell growth,
cell size, and cell division are co-regulated to ensure cells are large
enough to divide at mitosis (114). Studies in yeast reveal a size
requirement for G1-S transition, with smaller cells delaying in G1
until a sufficient size was reached to maintain viable progeny after
cell division (115, 116). Complementary studies in animal cells
show that mammalian cells also delay in G1 to allow an appro-
priate cell size to be achieved (117, 118). A plausible hypothesis
that combines both these observations is that the larger polyploid
tumor cells arrest during G0/G1 to allow for a sufficient growth to
occur before committing to division, which is hampered due to the
increased transcription and translational demands placed on poly-
ploid tumor cells by their elevated and unbalanced chromosomal
copy number.
Thus increased ploidy provides a general resistance mecha-
nism (that of infrequent cell cycle) to tumor cells, which are
well-positioned to contribute to the rapid evolution of patient
tumors during conventional chemotherapy and radiotherapy
regimes.
THE ROLE OF GIANT POLYPLOID CELLS IN THERAPY RESISTANCE AND
TUMOR REPOPULATION AFTER THERAPY
Giant polyploid cells are formed if DNA replication is uncoupled
from mitosis (119). This process has been termed the endocycle
and is a characteristic of p53-null cells (120), which is further
increased by exposure to radiation (121). It was thought that the
process of endocycles was irreversible and the resulting giant poly-
ploid cells represent a reproductive dead end (122). However two
back-to-back manuscripts suggested that giant polyploid cells may
provide an escape mechanism from severe genotoxic damage. The
first study followed p53-null cells after genotoxic insult, noting that
after delaying at G2/M for several days the cells enter endoreplica-
tion cycles that generate giant polyploid cells (123). Although the
majority of giant polyploid cells die, a small subset survive that are
able to produce viable progeny cells as determined using sensitive
clonogenic assays (123). Viable giant polyploid cells appear to fol-
low a defined path of chromosome re-organization that involves
reconstructing nuclei into polyploidy “bouquets,” which subse-
quently return to an interphase state and separate into secondary
nuclei (124). These secondary nuclei give rise to secondary cells in
a manner reminiscent of the life-cycles of protozoa (124).
Looking at two forms of transformation, carcinogen-induced
transformation of p53+/+ cell lines and spontaneous transforma-
tion of p53−/− cell lines Sundaram et al. reported a transformation
process that involved giant polyploid cell intermediates (125).
Here, the giant polyploid cells undergo a novel type of cell divi-
sion that involves nuclear budding within the giant polyploid
cells followed by intracellular cytokinesis to produce mononuclear
daughter cells that bud off the parental giant polyploid mother
cells (125). These mononuclear daughter cells are transformed,
displaying anchorage-independent growth (a classical hallmark
of cellular transformation) (125). A series of follow-up studies
provided strong support for the hypothesis that a subset giant
polyploid cells undergo some form of reductive division to pro-
duce small cells with near-diploid chromosomes that are prolif-
erative and competent to re-initiate tumor growth (reviewed in
Ref. (126)]. Interestingly, irradiated giant polyploid cells activate
key meiotic genes that are involved in metaphase arrest, genetic
recombination, and reductive divisions that occur during meio-
sis, indicating that giant polyploidy reductive divisions are likely
“meiosis-like” in nature (127–130).
Puig et al. undertook a systematic study using xenograft in vivo
models and in vitro approaches to characterize the role of giant
polyploid cells in therapy response to cisplatin (131). Cisplatin
treated tumors initially undergo shrinkage, and are increasingly
populated with giant non-proliferating tumor cells that main-
tain DNA synthesis (131). After several weeks of latency tumor
growth recurs, driven by a small fraction of proliferating cells
(131). Cells treated in vitro using clinically relevant cisplatin doses
also generate giant polyploid cells, a subset of which are able
to generate colonies of rapidly cycling small diploid cells. This
recapitulated the in vivo disease recurrence and suggested that
giant polyploid cells are active contributors to disease progres-
sion after therapy (131). Intriguingly, the proliferative diploid cells
generated from giant polyploidy cells have altered karyotypes and
display increased resistance to cytotoxic drugs (131), suggesting
for the first time that giant polyploid cells actively contribute to
the evolution of therapy resistance.
Very recent work studying ovarian cancer has underscored the
importance of giant polyploid cells in cancer disease progression
and therapy resistance (132). Zhang et al. purified giant polyploid
cells from established ovarian cancer lines and patient tumors,
and confirmed that these cells can initiate tumors in vivo and
are resistant to cisplatin cytotoxic therapy (132). Like previous
studies, Zhang et al. confirmed that giant polyploidy cells cycle
infrequently and generate smaller near-diploid progeny through
budding and bursting mechanisms (132). In this way, giant poly-
ploid cells are posited to function in a manner analogous to spores
in lower organisms, surviving harsh conditions to facilitate rapid
repopulation after stressful conditions have subsided (132, 133).
POLYPLOIDY, EMT, AND THE CANCER STEM-CELL PHENOTYPE
Cells with a primitive, undifferentiated phenotype tend to cycle
infrequently and display enhanced DNA repair, making them dif-
ficult to kill using cytotoxic and genotoxic therapies that preferen-
tially target actively cycling cells (134–136). The underlying drivers
leading to the generation of a primitive phenotype in patient
tumors remain incompletely understood. It has been reported
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that the frequency of CSC’s increases after treatment with geno-
toxic therapies (137–139). Salmina et al. tested the hypothesis
whether polyploidy, which allows cells to survive cytotoxic therapy
to continue proliferation, is also capable of endowing cells with a
primitive cell phenotype (140). They found that irradiated giant
polyploidy cells caused up regulation of the self-renewal stem-
cell genes OCT4 and NANOG, and that the NANOG, OCT4, and
SOX2 proteins were concentrated onto nuclear foci in giant poly-
ploidy cells (140). The giant polyploid cells resisted apoptosis,
overcame TIS, and transmitted the NANOG-OCT4-SOX2 self-
renewal program to their progeny (140). Subsequently Lagadec
et al. reported that ionizing radiation reprogramed differenti-
ated breast cancer cells toward an undifferentiated CSC state
(141). Strikingly, CSC reprograming only occurred within poly-
ploidy subpopulations, and involved re-expression of the tran-
scription factors OCT4, NANOG, sex determining region Y-box 2
and Klf4 (141). More recently, Zhang et al. demonstrated that
ovarian cancer giant polyploid cells displayed the CSC prop-
erties of CD44+/CD133+ expression, generation of spheroids
under serum-free culture conditions, increased tumorigenicity,
and elevated therapy resistance (132).
Cancer cells can also undergo epithelial to mesenchymal tran-
sition (EMT), where the cancer cells activate an evolutionarily
conserved trans-differentiation program that is used during mor-
phogenesis to convert differentiated epithelial cells into migratory
mesenchymal cells [reviewed in Ref. (142)]. Cancer cells under-
going EMT not only adopt an invasive cell phenotype that can
drive metastasis, but may also enter a drug refractory state due
to epigenetic reprograming (142). Recent work has revealed that
polyploidy facilitates EMT, with Zhang et al. showing that giant
polyploid tumor cells gain a mesenchymal phenotype (132) that
correlates with increased expression levels of EMT transcriptional
factors (143). These data suggest that polyploidy can facilitate
EMT, providing access to cell phenotype that is both invasive and
resistant to a variety of therapies.
Together, these studies provide compelling support for the
hypothesis that polyploidy drives the acquisition of undifferen-
tiated, primitive cellular phenotypes in human cancer. These cell
phenotypes can potentially increase therapy resistance, provide an
elevated tumor initiation capacity, and increase both the invasive
and metastatic potential of tumor cells.
PLOIDY-INDUCED ESCAPE FROM TARGETED ANTI-CANCER THERAPIES
Strong evidence supporting the role of polyploidy in evolving
solutions to targeted therapy has come from mouse models of
cancer. A defective spindle assembly checkpoint (SAC) results in
“mitotic slippage,” where cells exit mitosis without undergoing
anaphase or cytokinesis to produce a tetraploid cell [reviewed in
Ref. (69)]. As essential component of the SAC is Mad2, and Mad2
over-expression commonly occurs in many human cancers and
is associated with poor prognosis [reviewed in Ref. (68)]. Over-
expression of Mad2 increases the frequency of mitotic slippage and
tetraploidy (68, 69), and promotes tumorigenesis in mice (69).
In a doxycycline-inducible K-Ras model of cancer, Sotillo and
colleagues explored how Mad2 over-expression determined the
tumors ability to escape inhibition of the primary oncogenic dri-
ver K-Ras (144). In these experiments, Sotillo et al. allowed K-Ras
tumors to form in the presence or absence of Mad2, revealing
that the presence of Mad2 expression increased the aggressiveness
of the K-Ras tumor, as indicated by increased invasion, elevated
proliferative index, and a significant decrease in overall survival
(144). When doxycycline was removed, K-Ras and Mad2 expres-
sion was lost, leading to tumor regression in all animals. K-Ras
only tumors recurred rarely, however the tumors expressing both
K-Ras and Mad2 displayed a marked increase in recurrence rate,
driven by activation of a variety of compensating transforming
pathways (144). This finding supports the hypothesis that CIN
increases the probability of disease relapse during targeted therapy
by facilitating alternate pathway activation that allows tumor cells
to avoid the effects of targeted therapy (144). Further, this study
highlights how aneuploidy and oncogenes can act synergistically
during tumor initiation and cancer evolution.
The proteasome inhibitor, bortezomib, has forged new hori-
zons in the treatment of multiple myeloma (MM) (145). Although
efficacious, bortezomib is non-curative for MM because patients
eventually evolve therapy resistance. However, the underlying
resistance mechanisms remain poorly understood (146). To begin
to characterize resistance mechanisms, Balsas et al. generated
bortezomib-resistant MM lines that displayed five to sixfold
increased resistance to bortezomib (147). Unexpectedly, the target
of bortezomib (PSMβ5, the β5 subunit of the proteasome) was
not mutated, but was instead significantly overexpressed at both
the mRNA and protein levels within resistant cells (147). In addi-
tion, the bortezomib-resistant cells had evolved a near-tetraploid
genomic content, which also displayed cross-resistance to other
chemically unrelated proteasome inhibitors (147). Together, these
data provide direct support for the hypothesis that, as for yeast,
increasing genomic content allows cancer cells to circumvent
targeted therapy through over-expression of the therapy target.
An interesting and unwelcome twist to the use of targeted
therapy came from study of Sharma et al. (148). When Sharma
et al. treated several breast cancer lines with the tyrosine kinase
inhibitor BMS-777607, they noted that the surviving cell popula-
tion displayed elevated levels of polyploidy due to an increase in
the incidence of failed cytokinesis caused by off-target inhibition
of Aurora kinase B (148). They tested the surviving polyploidy cells
for sensitivity toward a range of chemotherapeutics (doxorubicin,
bleomycin, cisplatin, methotrexate, and paclitaxel), and found that
the therapy-induced polyploidy cells were resistant to all classes of
chemotherapies tested (148). This finding is reminiscent of an evo-
lutionary study undertaken in yeast, where transiently targeting
the function of Hsp90 protein led the chromosomal gains and the
rapid evolution of therapy-resistance toward unrelated cytotoxic
compounds (149).
Together these studies reveal that tumor cell polyploidy gener-
ates resistance toward targeted therapy. Of concern is the finding
that treating tumor cells with targeted therapies can elevate levels
of polyploidy in tumor cell populations, which then increases the
risk of developing multi-drug-resistance within clinical settings.
MEASURING THE PREVALENCE OF POLYPLOID TUMOR CELLS IN
CANCER
How many polyploid cells are there in patient tumors? Quan-
titation of polyploidy in patient cell lines and primary tumors
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is challenging due to the infrequent cell cycle of polyploid
tumor cells. Cancer cell biologists have traditionally used a flow-
cytometry approach, where they estimate the frequency of poly-
ploidy by measuring the number of cells with greater than 4n DNA
content. However, this approach can only detect polyploid cells
that are actively cycling, because most of the polyploid tumor cells
are tetraploid or near-tetraploid, and therefore remain indistin-
guishable from the G2/M cells of the “diploid” tumor population.
More sophisticated metaphase analyses [for example those in Ref.
(62)] are also likely to underestimate the frequency of polyploid
tumor cells, because their infrequent cell cycle means they will
be under-represented using a metaphase-dependent karyotypic
analysis.
Flow-cytometry screens can utilize the expression of Cyclin-B1
to discriminate between the cycling tumor “diploid” cells that are
transitioning through the G2/M phase of the cell cycle, from the
polyploid tumor cells in that are in the G0/G1 phase of the cell
cycle (Figure 1). The advantage of this assay is that it allows the
assessment of large populations of cells (in this example, 100,000
single cells for each patient line were analyzed), and the inclusion
of a control line in the same tube means that the ploidy levels
of tumor cells relative to control cells can be estimated within
the same assay under identical staining conditions, eliminating
the confounding effects of cell number variation between tubes
[Figure 1; Ref. (110)]. Here, we use the prodrug carboxyfluores-
cein diacetate succinimidyl ester (CFSE), which is converted by
cellular esterase activity into a fluorescent compound covalently
bound to proteins and retained within the cells (150). CFSE stain-
ing clearly delineates the CFSE-stained control from the unstained
test cell populations, and the control and test cell populations are
readily identified using standard flow-cytometry gating strategies
(110). CFSE-stained control lines can be either healthy diploid cells
to provide a more accurate estimate of DNA content [(110) and
shown in Figure 1], or alternatively untreated tumor cells can be
used to directly compare the effect of drug treatments on the preva-
lence of polyploidy during compound screening or pre-clinical
testing. Because control cells are stained with CFSE immediately
before fixation (110), the staining process has no effect on cell
ploidy or viability and is therefore unlikely to generate Type I or
Type II errors during compound screening.
Using this method, we assessed the prevalence of polyploidy
in 10 low-passage primary patient glioblastoma lines (Figure 1),
cultured under tumorsphere conditions, a culture method that
preserves the genotype, and phenotype of the original tumor
(151). In 10 primary patient tumor lines, the lowest frequency
of tumor cell polyploidy was 1 in 20 cells (i.e., 5% of the total
tumor cell population were polyploid). To put this into context,
it is estimated that a 1 g solid tumor contains 108–109 tumor
cells (74, 152). If the lowest polyploid estimate of 5% is applied,
then between 5 and 50 million rapidly evolving, therapy-resistant
polyploid tumor cells will be present in brain cancer patients that
have tumor volumes of 1 cm3.
AN INTEGRATED MODEL EXPLAINING HOW INCREASED
GENOMIC CONTENT FACILITATES CANCER EVOLUTION
From the perspective of cancer as an evolutionary disease, we argue
that the studies summarized above provide sufficient grounds for
FIGURE 1 | An improved flow-cytometry assay for measuring the
prevalence of polyploidy in tumors cell populations. (A) Tumor cell
samples are spiked with carboxyfluorescein diacetate succinimidylester
(CFSE) stained primary neonatal foreskin fibroblasts (NFF) diploid control.
The CFSE-negative tumor cells shown in blue are readily gated from the
CFSE-high NFF diploid controls, shown in red. (B) DNA content of the
Glioblastoma tumor cells (blue histogram) overlayed onto the NFF diploid
control histogram, shown in red. Most Glioblastoma cell lines that we have
studied are aneuploid with a slightly hyperdiploid DNA content, and contain
a small sub-population of cells that are near-tetraploid with respect to the
tumor bulk population (i.e., pseudo-polyploid). (C) A typical polyploidy
flow-cytometry assessment utilized by many cancer cell biologists, who
use the proportion of live single cells with greater than 4n DNA (shown
within the red gate) as being representative of the total pseudo-polyploid
population. In this example, 4.5% of the total cells are classed as
pseudo-polyploid. (D) The same tumor sample assessed for
pseudo-polyploidy using Cyclin-B1 staining to discriminate between the
G2/M (the Cyclin-B1 high cells with a 4n DNA content) population of the
pseudo-diploid bulk, from the pseudo-diploid G0/G1 population (the
Cyclin-B1 low cells with a 4n DNA content). The pseudo-polyploid gate
(shown in red) identifies both the cycling and the non-cycling
pseudo-polyploid tumor cells, which make up approximately 22% of the
total tumor cell population. (E)Ten low-passage primary patient glioblastoma
cell lines, grown under serum-free tumorsphere conditions, assessed for
pseudo-polyploidy using the Cyclin-B1 gating strategy from (D). In eight
lines, the dominant cell population was aneuploidy with a near-diploid DNA
content, with a sub-population of pseudo-polyploid cells that made up
5–38% of the total cell population. In contrast, two glioblastoma lines were
pre-dominantly pseudo-polyploid (65 and 78%), with a small of near-diploid
sub-population. Detailed staining protocols are provided in Ref. (110).
the development of an updated model of cancer that highlights
a central role of polyploidy during tumorigenesis and disease
progression (Figure 2). The hallmarks of cancer outlined by
Hanahan and Weinberg (153) clearly highlight the selection pres-
sures that must be overcome on the journey from pre-malignant
lesion to full-blown cancer. The early selection pressures include
apoptosis, senescence and terminal differentiation. We argue that
pre-malignant polyploid cells are more likely to overcome these
barriers than diploid pre-malignant cells. Polyploidy enables epi-
genetic silencing of p53 (84), reducing the probability of apoptosis
and weakening the senescence barrier. Polyploidy also rewires the
DNA-damage response (84), further subverting the senescence
barrier and increasing the probability of pre-malignant polyploid
cells re-entering the cell cycle (84). The vast majority of cells
are terminally differentiated. Differentiated pre-malignant cells
must somehow overcome the terminal differentiation program,
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FIGURE 2 | An integrated model of tumor evolution highlighting
potential roles of polyploidy during cellular transformation. Here, we
present a simplified view of disease progression, highlighting the role of
polyploidy in overcoming selection pressures to drive the evolution of
cellular transformation. The fist selections pressures pre-malignant lesions
must overcome are those of apoptosis, senescence and terminal
differentiation. Polyploidy enables adaptation to these barriers by silencing
p53 remove p53-dependent pro-apoptotic and senescence signaling,
rewiring the DNA-damage response to suppress p53-independent
senescence programs, and enabling acquisition of primitive stem-cell
phenotypes. Once a proliferative state is reached, polyploidy increases the
acquisition of transforming mutations by increasing chromosomal
instability and buffering the proliferative cells against the effects of
deleterious mutations. Polyploidy also increases glycolysis, enabling
survival in low oxygen environments, and enables EMT and the generation
of invasive and metastatic phenotypes. Polyploid cells provide multiple
mechanisms of therapy resistance, buffer the cancer genome against
deleterious mutation resulting from genotoxic therapies, and generate
primitive tumor-initiating phenotypes that are capable of driving disease
recurrence. Throughout this process, tumor heterogeneity and karyotypic
complexity increases, which in turn increase the heterogeneity and
evolutionary capacity of the tumor.
revert to an undifferentiated phenotype, and reclaim the unlim-
ited proliferative capacity of multi-potent stem cells (154). We
now know that polyploidy facilitates acquisition of a primitive,
stem cell like phenotype (132, 140, 141), although the underlying
mechanisms remain incompletely uncharacterized.
Once pre-malignant cells circumvent these initial selection
pressures to generate a proliferative phenotype, they must then
acquire further transforming mutations to overcome subsequent
selection pressures such as immune-surveillance, metabolic stres-
sors, and the effects of deleterious mutation (154). Polyploidy is
likely to facilitate the rapid acquisition of new transforming muta-
tions in two ways. First, elevated ploidy reduces the lethality of
deleterious mutations and chromosome loss (44, 73, 74). Second,
polyploidy increases CIN (70, 71, 73, 141, 155, 156), which elevates
karyotypic variation within the tumor cell population through
large-scale genetic change (74). Hence, polyploidy enables both
CIN and mutator phenotypes, thereby greatly increasing the speed
at which proliferating tumor precursor cells can acquire the port-
folio of mutations and the oncogenic karyotypes necessary for
full-blown transformation (3, 61). In addition, polyploidy can help
overcome metabolic stress by contributing to metabolic repro-
graming, invasion, and metastasis. Polyploid tumor cells display
elevated levels of anaerobic glycolysis (110, 157) and are highly
resistant to oxygen deprivation (132). Polyploid tumor cells also
increase the expression of metastasis-related proteins (143), which
may enable the acquisition of metastatic phenotypes by driving
EMT (132).
Once disease presents and treatment commences, polyploid,
and hyperdiploid cells remain key players driving the ongoing evo-
lution of the patient disease. Elevated ploidy provides cells with
multiple therapy-resistance mechanisms including infrequent cell
cycle (110, 132), acquisition of primitive, therapy-resistant cell
phenotypes (132, 158), over-expression of therapeutic targets
leading to resistance (147), alternate pathway activation lead-
ing to therapy escape (144), as well as facilitating acquisition of
the dreaded multi-drug resistant phenotype (148, 149). Polyploid
tumor cells are created by cytotoxic and targeted therapies (149,
158–160), therefore the frequency of tumor cells with elevated
ploidy is likely to significantly increase during therapy. Further,
many front-line therapies are genotoxic mutagens. In this scenario,
the therapy itself imparts a mutator phenotype onto the tumor,
with polyploidy functioning as a genetic buffer to reduce the effects
of deleterious mutations, increasing the probability of beneficial
mutations surviving within the polyploidy sub-population to drive
disease recurrence.
The adaptive capacity inherent to polyploidy cells means that
even a small sub-population of surviving polyploid tumor cells are
able to drive disease recurrence (39,161). The capacity of polyploid
tumor cells to repopulate post-therapy is likely to be significantly
enhanced due to the ploidy-driven acquisition of a primitive cell
phenotype with an elevated tumor-initiating capacity (132, 141),
combined with a greatly reduced competition for resources due
to the competing non-resistant tumor cells being killed off during
therapy (162).
For these reasons, we predict that polyploid tumor cells play
an integral role in disease recurrence and the acquisition of
a therapy-resistant, increasingly malignant disease in patients
during therapy.
NEW THERAPEUTIC STRATEGIES THAT TARGET POLYPLOIDY
AND HYPERDIPLOID TUMOR CELL SUBPOPULATIONS
Experiments in yeast and cancer model systems have shown that
the presence of polyploidy generates points of fragility within
cellular systems that can be targeted using specific therapeutics
(163–168). These studies provide the critical proof-of-principle
that polyploidy is in fact a druggable phenotype. However,
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the strategies proposed in these pioneering studies target stress
responses or mitotic machinery, which poses the risk of increas-
ing polyploidy in surviving cells (148, 149). Fortunately, recent
studies have identified new avenues for therapy development that
could be used in conjunction with established therapies to inhibit
the formation of polyploidy tumor cells and decrease the adaptive
capacity of tumors in vivo.
TARGETING METABOLISM TO ATTACK POLYPLOIDY AND
HYPERDIPLOID TUMOR CELLS
Cell size scales linearly with DNA content in Eukaryotes (169–
172). Cancer polyploid cells are proportionally larger than the
euploid bulk population (110, 147), with giant polyploid cells
being much larger than the euploid population (124). One poten-
tial consequence of large genome size and increased cell volume
is a heightened metabolic demand, as bigger cells require more
energy to grow to a sufficient cell volume to allow for cell doubling
(117, 118). Further, the increased mRNA and protein expression
caused by increased ploidy also demands more energy consump-
tion (37). Consistent with increased genome size cell volume, and
elevated transcription and translation, we noted polyploid tumor
cells displayed a higher metabolic rate than the euploid control
population (110).
The large cell size and increased metabolism of polyploid tumor
cells may represent a point of fragility specific to the polyploid
sub-population that could be exploited therapeutically. To test
this hypothesis, we treated parental euploid and polyploid clonal
cultures with the 2-deoxy-d-glucose, an established inhibitor of
glycolysis (173–176). We found that the brain tumor polyploid
cells were significantly more sensitive to the effects of glycolysis
inhibition then the euploid parent control (110).
Critically, this increased dependence of polyploidy cells on gly-
colysis has been reported across several types of cancer. In acute
myeloid leukemia (AML), Liu et al. demonstrated that target-
ing aurora kinases with specific inhibitors increased the preva-
lence of polyploidy in AML cells, and that AML polyploidy cells
displayed increased glycolysis as measured by increased glucose
uptake and lactic acid production (157). AML polyploidy cells
were sensitive to the effects of 2-DG, suggesting that targeting
metabolism may preferentially kill polyploidy tumor cells (157).
mTOR is a conserved serine/threonine kinase that links cell sig-
nal transduction with cell metabolism and growth (177). Specific
mTOR inhibitors promoted apoptosis and autophagy in poly-
ploidy tumor cells and increased the efficacy of Aurora kinase
inhibitors, confirming tumor metabolism as a viable point of ther-
apeutic intervention against AML polyploidy tumor cells (157).
Using breast cancer cells, Sharma et al. used the tyrosine kinase
inhibitor BMS-777607 to induce polyploidization in breast cancer
lines, and confirmed that therapy-induced polyploidy cells were
resistant to the effects of a variety of chemotherapies (148). They
then performed drug screens looking for additional inhibitors that
specifically targeted polyploidy tumor cells, and identified that an
inhibition of mTOR signaling prevented the formation of therapy-
induced polyploidy and maintained the sensitivity of breast cancer
cells toward the effects of chemotherapies (148). These results
indicate that reducing polyploidy tumor cell formation by tar-
geting metabolism may delay the evolution of therapy resistance
(148). More recently, the same group revealed that BMS-777607
induced polyploidization in pancreatic cancer cells, which dis-
played pan-resistance to a range of chemotherapeutic compounds
(160). Targeting metabolism using mTOR inhibitors reduced the
formation of therapy-resistant polyploidy cells and synergized
with BMS-770607, showing that for pancreatic tumor cells target-
ing tumor metabolism prevents the emergence of therapy-resistant
polyploidy tumor cells (160).
Together, these results support the hypothesis that in brain,
breast, leukemia, and pancreatic cancers, polyploid tumor cells
have a commensurately higher metabolic requirement than
euploid tumor cells, and that inhibiting metabolism is an effective
therapeutic strategy to specifically target polyploid tumor cells to
maintain tumors in a drug sensitive state.
STIMULATING AMP KINASE ACTIVITY USING RESVERATROL AND
ASPIRIN
Lissa et al. used an elegant high-throughput screening to screen
a compound library for drugs that preferentially kill tetraploid
cells, identifying resveratrol as an anti-tetraploid therapeutic agent
(178). Resveratrol is an anti-fungal agent naturally occurring in
grapes that has been reported to reduce tumor formation in a
genetic mouse model of intestinal carcinoma when administered
orally (179). Resveratrol stimulates AMPK activation by inhibit-
ing phosphodiesterase 4 (PDE-4), allowing cAMP accumulation
in cells and subsequent activation of protein kinase A (PKA) (180).
Consistent with this being the primary mode of tetraploid killing,
resveratrol treatment activated AMPK in tetraploid cells (180).
Activation of AMPK using a separate PDE-4 inhibitor or over-
expression of AMPK selectively killed tetraploid cells, whereas PKA
inhibitors specifically blocked resveratrol killing (178). Aspirin
(acetyl salicylate) and it is more active derivative salicylate also
activate AMPK, and consistent with other AMPK activators were
shown to selectively kill tetraploid cells (178). Using the mouse
intestinal carcinoma cancer model, the Authors then confirmed
that oral administration of either resveratrol or aspirin reduced
the frequency of tetraploid intestinal epithelial cells (178), con-
firming that resveratrol and aspirin preferentially kill tetraploid
cells in vivo using clinically relevant therapeutic doses (178).
Together, these data show that activating AMPK using the nat-
ural products resveratrol and aspirin can be used to specifically tar-
get tetraploid tumor cells in vitro and in vivo,potentially explaining
the cancer-preventing effects of these two compounds reported
using mouse models of tumor initiation (181). These findings
support the exciting hypothesis that targeting tetraploid malig-
nant precursor cells may become an effective chemopreventative
strategy for humans.
CONCLUSION AND FUTURE DIRECTIONS
Cancer evolution has been intensely studied in recent years
using cutting edge genomic approaches (182–185), and novel
therapeutic strategies aimed at delaying tumor evolution are
being developed using increasingly sophisticated and predictive
computational models of tumor evolution (162, 186–189). Here,
we have presented a complementary approach, which consists of
identifying and therapeutically targeting the polyploid tumor cell
subpopulations that are likely to facilitate rapid evolution. We have
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based our argument on evidence derived from yeast and cancer
model systems, as well as from primary patient tumor samples, all
of which support the hypothesis that polyploidy facilitates rapid
evolution and the acquisition of therapy-resistant phenotypes in
cancer patients.
We have also presented recent studies that identify promising
new anti-polyploid therapeutic approaches, which could poten-
tially be used to target polyploid tumor cells in cancer patients. We
predict that the therapies stemming from these pioneering studies
will be successfully translated and incorporated into novel anti-
evolution therapies designed using systems biology approaches,
which will significantly increase cancer patient lifespan by slow-
ing the emergence of therapy resistance, as well as being used as
chemopreventative agents to reduce the incidence of cancer.
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